Clinical Trials Browser

Lymphoma, B-Cell, Marginal Zone × tafasitamab × 90 days × Clear all

NCT04646395 2026-04-06

Study of Acalabrutinib and Tafasitamab in MZL Patients

Phase 2 Active not recruiting

Lymphoma, B-Cell, Marginal Zone